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Abstract. 
 
Utrophin is a dystrophin-related cytoskeletal 
protein expressed in many tissues. It is thought to link 
F-actin in the internal cytoskeleton to a transmembrane 
protein complex similar to the dystrophin protein com-
plex (DPC). At the adult neuromuscular junction 
(NMJ), utrophin is precisely colocalized with acetylcho-
line receptors (AChRs) and recent studies have sug-
gested a role for utrophin in AChR cluster formation or 
maintenance during NMJ differentiation. We have dis-
rupted utrophin expression by gene targeting in the 
mouse. Such mice have no utrophin detectable by 
Western blotting or immunocytochemistry. Utrophin-
deficient mice are healthy and show no signs of weak-
ness. However, their NMJs have reduced numbers of 
AChRs (
 
a
 
-bungarotoxin [
 
a
 
-BgTx] binding reduced to 
 
z
 
60% normal) and decreased postsynaptic folding, 
though only minimal electrophysiological changes. 
Utrophin is thus not essential for AChR clustering at 
the NMJ but may act as a component of the postsynap-
tic cytoskeleton, contributing to the development or 
maintenance of the postsynaptic folds. Defects of utro-
phin could underlie some forms of congenital myas-
thenic syndrome in which a reduction of postsynaptic 
folds is observed.
 
U
 
trophin
 
 is a component of the membrane cyto-
skeleton, found in many tissues. It is a close ho-
mologue of dystrophin (reviewed in Blake et al.,
1996), which causes the severe muscle wasting disease in
man, Duchenne muscular dystrophy (Hoffman et al., 1987;
Koenig et al., 1988). Both proteins are thought to link the
internal cytoskeleton of the muscle cell to the extracellular
matrix (reviewed in Ahn and Kunkel, 1993; Tinsley et al.,
1994; Campbell et al., 1995). The NH
 
2
 
-terminal region of
dystrophin binds F-actin while the COOH-terminal region
binds to 
 
b
 
-dystroglycan, a component of the dystrophin
protein complex (DPC)
 
1
 
 (Ervasti et al., 1990; Ervasti and
Campbell, 1991; Ibraghimov-Beskrovnaya, 1992). 
 
a
 
-Dys-
troglycan, a further component of the DPC, is thought to
bind to laminin in the extracellular matrix (Ohlendieck
and Campbell, 1991; Dickson et al., 1992; Ervasti and
Campbell, 1993). Utrophin shares 85% amino acid conser-
vation with dystrophin in the NH
 
2
 
- and COOH-terminal
regions (Love et al., 1989; Tinsley et al., 1992) and is likely
to have similar binding partners (Matsumura et al., 1992;
Winder et al., 1995; Winder and Kendrick-Jones, 1995;
James et al., 1996).
Unlike dystrophin, which is only expressed in muscle
and brain in the adult, utrophin is expressed in a wide vari-
ety of adult tissues. The presence of utrophin in vascular
smooth muscle and the endothelium appears to underlie
its very general tissue distribution with highest levels of
protein and mRNA expression in lung and kidney (Love
et al., 1989, 1991; Schofield et al., 1993). Utrophin appears
early in the development of the mouse with the first tran-
scripts detectable in the neural groove at embryonic day
8.5 (Schofield et al., 1993). Subsequent utrophin expres-
sion is particularly abundant in a subset of tissues derived
from the neural crest such as peripheral nerve where it
colocalizes with dystroglycan and homologues of other
dystrophin-associated proteins (Matsumura et al., 1993).
In many tissues and cultured cells, utrophin is present at
specialized cell–cell or cell–extracellular matrix contacts.
These include the foot processes of the kidney filtration
barrier, the bronchial wall of the alveoli, and the interca-
lated discs of the heart (Pons et al., 1994) as well as focal
adhesions and adherens-type junctions (Belkin et al., 1994;
Belkin and Burridge, 1995). In brain, in addition to its en-
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1. 
 
Abbreviations used in this paper
 
: AChE, acetylcholinesterase; AChR,
acetylcholine receptor; 
 
a
 
-BgTx, 
 
a
 
-bungarotoxin; DIA, diaphragm; DPC,
dystrophin protein complex; EDL, 
 
extensor digitorum longus
 
; ETA,
 
epitrochleoanconeus
 
; NMJ, neuromuscular junction; SOL, 
 
soleus.
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richment in vascularized regions and in the astrocyte foot
processes of the blood-brain barrier (Khurana et al., 1992),
utrophin is reported to be present in the postsynaptic re-
gion of some synapses (Kamakura et al., 1994). In adult
skeletal muscle fibers, in contrast to dystrophin, utrophin
is present only at the neuromuscular junction (NMJ) and the
myotendinous junction (Ohlendieck et al., 1991; Nguyen
thi Man et al., 1991; Bewick et al., 1992), although a more
general distribution is found in embryonic and regenerat-
ing muscle (Khurana et al., 1991; Helliwell et al., 1992;
Karpati et al., 1993; Koga et al., 1993; Sewry et al., 1994).
The NMJ is a cell–cell junction where utrophin is nor-
mally associated with an essential ligand-gated ion chan-
nel, the acetylcholine receptor (AChR). The postsynaptic
membrane of the NMJ is characterized by extensive fold-
ing. Utrophin precisely colocalizes with the AChRs at the
crests and upper part of these folds, while dystrophin and
 
b
 
-spectrin are concentrated with voltage-gated sodium
channels in the depths of the folds (Flucher and Daniels,
1989; Bewick et al., 1992; Sealock et al., 1991). This colo-
calization of utrophin and AChRs is present in the embryo
from the earliest stage of AChR clustering and throughout
the postnatal maturation of the NMJ (Phillips et al., 1993;
Bewick et al., 1996) as is rapsyn, a NMJ-specific protein
known to be essential in AChR clustering (Froehner et al.,
1990; Phillips et al., 1991; Gautam et al., 1995). In contrast,
dystrophin and spectrin do not appear at the NMJ until
well after AChR clusters have formed (Bewick et al.,
1996). Further evidence for a link between utrophin and
the AChRs comes from the finding that utrophin is greatly
reduced at the NMJ in some acquired and inherited AChR
deficiencies in man whereas dystrophin and several other
postsynaptic proteins are not (Slater et al., 1994). Finally,
in addition to its synapse-specific location in muscle cells,
expression of the utrophin gene may also be controlled by
synapse-specific factors. The promoter region of utrophin
has recently been found to contain an N-box motif, which
is also present in the genes for the 
 
d
 
 subunit of the AChR
and 
 
b
 
2-syntrophin which are preferentially expressed at
the NMJ (Dennis et al., 1996).
The pattern of expression of utrophin suggests that it
may be involved in the development and maintenance of a
wide variety of tissues. The large size of the utrophin gene,
like that of dystrophin, makes it a likely candidate for nat-
ural mutation (Pearce et al., 1993). Nonetheless, no natu-
rally occurring diseases of man or animals have been iden-
tified as resulting from mutations of the utrophin gene,
possibly because such mutations are always lethal. To in-
vestigate the function of utrophin, we therefore created
mice with a null mutation in the utrophin gene. We fo-
cused much of our attention on characterizing the effects
of the lack of utrophin on the properties of the NMJ.
 
Materials and Methods
 
Gene Targeting Construct
 
Restriction and modifying enzymes were used following the manufac-
turer’s instructions (Boehringer Mannheim, Lewes, UK or Biolabs). Ra-
dioactive label was obtained from Amersham International (Amersham,
UK) or ICN (Thane, UK). The 129/Sv library (kindly donated by Terry
Rabbitts, Cambridge, UK) was screened using a 5
 
9
 
-end human utrophin
cDNA clone (89.2; Tinsley et al., 1992). A 7-kb EcoRI fragment compris-
ing a single exon flanked by 3.5 kb of isogenic DNA on either side was
subcloned into pUC18. A 1-kb genomic EcoRI–EcoRV fragment located
at the 5
 
9
 
-end was subsequently removed for use as an external probe and
the remaining fragment was subcloned into pBluescript II SK
 
2
 
 (Strat-
agene, La Jolla, CA). A neomycin resistance cassette (neo) driven by the
phosphoglycerate kinase-1 (pgk) promoter was introduced into the
EcoRV site in the exon. 40 
 
m
 
g of targeting construct was released from
vector backbone by BamHI digestion and purified by gel electrophoresis
and Qiagen extraction before electroporation.
 
Transfection of R1 ES Cells and Generation of
utrn
 
2
 
/
 
2
 
 Mice
 
Methods were essentially those of Wurst and Joyner (1993) and Papaioan-
nou and Johnson (1993). ES cells (R1 ES cell line was kindly donated by
Andras Nagy, Mount Sinai Hospital, Toronto, Canada) were routinely
passaged on monolayers of mitotically inactivated primary embryonic fi-
broblast cells (made from CD1 mice) in ES cell culture medium (all
Gibco). 5 
 
3
 
 10
 
6
 
 ES cells were electroporated in 0.4-cm cuvettes in a Bio-
rad Gene Pulser at 0.34 kV/250 
 
m
 
F or 0.25 kV/500 
 
m
 
F. Transfected cells
were selected in ES cell medium containing 300 
 
m
 
g/ml G418 (Gibco).
G418 resistant colonies were cloned in 96-well plates and DNA prepared
for BamHI digestion. Correct targeting events were identified by South-
ern blot analysis using the 5
 
9
 
 flanking probe and the internal neo probe.
Two targeted clones were injected into 3.5-d-old C57BL6 blastocysts
which were transferred into ICR pseudopregnant females. 12 chimeras
were generated, of which 10 were male, all with 
 
z
 
95% coat color chimer-
ism. These were mated to DBA/C57 F1 females; 6 produced agouti off-
spring at a high percentage (being germline transmission of the mutated
ES cells). Southern blotting of genomic DNA from tail biopsies was used
to identify heterozygotes (
 
Utrn
 
1
 
/
 
2
 
), which were mated to produce ho-
mozygous offspring (
 
Utrn
 
2
 
/
 
2
 
).
 
RT-PCR/RNase Protection Analysis
 
RNA from homogenized tissues (lung, kidney, heart, skeletal muscle,
brain, diaphragm, and smooth muscle) was extracted using UltraspecTM
(Biotecx laboratories) and analyzed essentially as described by Dennis et
al. (1996).
 
Western Analysis
 
Tissues were homogenized in gel loading buffer (75 mM Tris-HCl pH 6.8;
3.8% SDS; 4 M urea; 20% glycerol) and the total protein content assessed
(Biorad DC Assay kit). After addition of 5% 
 
b
 
-mercaptoethanol and
0.001% bromophenol blue, 100 
 
m
 
g of each extract was separated on a
polyacrylamide gel (8% for dystrophin and utrophin; 12% for 
 
b
 
-dystrogly-
can) and electroblotted onto a nitrocellulose membrane. The membranes
were then incubated with antibodies to utrophin (MANCHO7), or dystro-
phin (MANDRA1, both used at 1/100; kind gifts of Dr. G.E. Morris), or
 
b
 
-dystroglycan (43DAG/8D5, used at 1/10; kind gift of Dr. L.V.B. Ander-
son), or 
 
a
 
-sarcoglycan (polyclonal, used at 1/50; kind gift of Dr. K.P.
Campbell, Howard Hughes Medical Institute, Iowa City, IA). Bound pri-
mary antibodies were detected by horseradish peroxidase–conjugated sec-
ondary antibodies followed by chemiluminescence (Boehringer).
 
Histology and Immunocytochemistry
 
All immunolabeling was done on 6-
 
m
 
m thick unfixed sections of muscle,
frozen in isopentane cooled in liquid nitrogen. All antibodies were applied
in PBS containing 3% bovine serum albumin and 100 mM lysine for 1 h at
room temperature. Primary antibodies against the following proteins were
used; utrophin (G3, polyclonal affinity purified, kind gift of Dr. C.A. Sewry,
London, UK; DRP1/12B6 and DRP3/20C5, monoclonals against the
COOH terminus and NH
 
2
 
 terminus, respectively, both used at 1/10, kind
gift of Dr. L.V.B. Anderson, Newcastle, UK; MANCHO7, monoclonal
against COOH terminus, used at 1/10 kind gift of Dr. G.E. Morris, MRIC
Biotechnology Group, Aberystwyth, UK), dystrophin (P6, polyclonal,
kind gift of Dr. C.A. Sewry, London, UK; DY8/6C5, monoclonal, used at
1/10, kind gift of Dr. L.V.B. Anderson, Newcastle, UK), dystroglycan
(43DAG/8D5, monoclonal against 
 
b
 
-dystroglycan, used at 1/100, kind gift
of Dr. L.V.B. Anderson, Muscular Dystrophy Group Research Labora-
tory, Newcastle, UK; polyclonal against 
 
a
 
, 
 
b
 
-dystroglycan, kind gift of Dr.
K.P. Campbell, IA), 
 
a
 
-sarcoglycan (polyclonal, kind gift of Dr. K.P. 
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Figure 1. Production of utrn2/2 mice. (a) Targeting vector, homologous genomic region with external probe region, and predicted
product of the homologous recombination event. Restriction enzymes are denoted as follows: BI (BamHI); RI (EcoRI); RV (EcoRV).
(b) Southern blot analysis of G418 resistant ES cell colonies; targeted events were identified by the presence of an additional band at 9.6
kb. (c) Southern blot analysis of tail biopsies from germline offspring; heterozygotes were identified by presence of targeted (9.6 kb) al-
lele. (d) Top: breeding of heterozygotes produced Mendelian ratios of 1/1 (8kb), 1/2 (8 kb and 9.6 kb), and 2/2 (9.6 kb); bottom: re-
probing with internal neo probe confirms hybridization only to the 9.6-kb band. (e) Western blot analysis of 1/1, 1/2, and 2/2 kid-
ney and lung and 1/1, 2/2 brain, showing absence of utrophin in 2/2 tissues; COS cells used as positive control for size of utrophin
(z400 kD). 
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Campbell, IA), rapsyn (polyclonal raised by A. Vincent against recombi-
nant rapsyn kindly provided by Dr. J.R. Sanes, St. Louis, MO).
Immunoreactivity was visualized using secondary antibodies conju-
gated with TRITC (DAKO), preincubated with normal rat serum. To
identify NMJs, AChRs were labeled in the same sections with FITC-
 
a
 
-
bungarotoxin (
 
a
 
-BgTx) (0.6 
 
3
 
 10
 
2
 
6
 
 M, Molecular Probes, Eugene, OR).
Labeled sections were mounted in Vectashield (Vector Labs, Burlingame,
CA). Sections incubated in diluent without primary antibody served as
controls for nonspecific binding of secondary antibodies. Utrophin was
also labeled in teased, permeabilized SOL muscle fibers, as described by
Bewick et al. (1992). Additional sections were stained with hematoxylin
and eosin for histological examination.
Labeling was recorded photographically using a Leica DMRBE micro-
scope or by a computer controlled cooled CCD camera (AstroCam 4100).
 
Creatine Kinase and Protein in Urine Assay
 
Mice were bled by tail biopsy under nonstressful conditions. 3 
 
m
 
l of serum
was assayed for creatine kinase activity (Boehringer Mannheim MPR 1
kit). Urine was collected and assayed for protein content (Sigma Micro-
protein kit).
 
AChR Quantification
 
AChR abundance was estimated from 
 
a
 
-BgTx binding which was assessed
in two ways; from radioactive 
 
a
 
-BgTx binding and from the intensity of
fluorescent 
 
a
 
-BgTx labeling.
To assess binding of radiolabeled 
 
a
 
-BgTx, freshly dissected muscles
were incubated in 
 
125
 
I-
 
a
 
-BgTx (200 
 
m
 
Ci/mM, Amersham), at a concentra-
tion of 0.5 
 
3
 
 10
 
2
 
8
 
 M in Liley’s solution (Liley, 1956) for 4 h at 20–22
 
8
 
C and
then washed. The muscles were then fixed (5% glutaraldehyde in 0.1 M
phosphate buffer, pH 7.2 for 1.5 h) and washed overnight at 4
 
8
 
C. Adult
muscles (diaphragm, DIA; 
 
soleus
 
, SOL; 
 
extensor digitorum longus
 
, EDL;
 
epitrochleoanconeus
 
, ETA) were teased into bundles of 10–20 fibers and
reacted to demonstrate AChE activity (Karnowsky and Roots, 1964). Re-
gions of the bundles containing NMJs were cut out along with an adjacent
piece, free of NMJs, of the same length. The pieces (15 pairs per muscle)
were mounted on slides and the number of NMJs in each piece counted
under the microscope. Separate pools were made of pieces with or with-
out NMJs and the total radioactivity in each pooled sample was deter-
mined in a 
 
g
 
 counter. At least two muscles of each type were analyzed and
the results averaged. For younger mice, the small and closely packed
NMJs could not be accurately counted. Hemidiaphragms with ribs at-
tached were incubated in 
 
125
 
I-
 
a
 
-BgTx, washed extensively, fixed, and re-
acted to demonstrate AChE activity as described above. Regions of dia-
phragms containing NMJs were then cut out with an adjacent, NMJ-free,
piece of the same length for radioactive counting. NMJ-specific 
 
125
 
I-
 
a
 
-
BgTx binding for each hemidiaphragm was determined after subtracting
non-NMJ binding per unit weight.
To determine the intensity of fluorescent 
 
a
 
-BgTx labeling, muscles 
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were incubated for 4 h at 20–22
 
8
 
C in TRITC-
 
a
 
-BgTx (Molecular Probes)
at a concentration of 0.6 
 
3
 
 10
 
2
 
6
 
 M in Liley’s solution. After washing, the
labeled muscles were fixed in 1% paraformaldehyde for 30 min, washed,
teased into small bundles, and mounted in Vectashield. The samples were
viewed in a fluorescence microscope and digitized images recorded using
a 50 
 
3
 
 objective with a cooled CCD camera (AstroCam 4100) for analysis
using IMAGER2/Visilog software. After thresholding by eye to define
the region of high AChR density at each NMJ, the area and average inten-
sity of fluorescence in the selected region were obtained.
 
Demonstration of AChE Activity and
Intramuscular Nerves
 
Muscles (DIA, SOL, EDL, and ETA) were fixed in 4% paraformalde-
hyde and then reacted to demonstrate AChE activity (Karnovsky and
Roots, 1964). Teased single fibers were then mounted on slides for obser-
vation. To visualize motor axons, some samples were then further stained
using a slightly modified version of the silver impegnation method of Tsuji
and Tobin-Gros (1980). Further details are given in Slater et al. (1992).
 
Ultrastructural Analysis
 
For ultrastructural studies, including localization of AChRs, fresh muscles
(DIA, SOL, EDL, and ETA) were incubated for 4 h (room temperature)
in biotin-
 
a
 
-BgTx (2.4 3 1026 M, Molecular Probes) in Liley’s solution and
washed before fixing in 2.5% glutaraldehyde in 0.1 M phosphate buffer,
pH 7.2 for 1.5 h on ice. Small bundles of fixed muscle fibers were reacted
with a streptavidin/biotin/HRP complex (DAKO) for 1 h and then reacted
with 39, 39-diaminobenzidine with H2O2. Small blocks containing NMJs
were then processed for electron microscopy as described by Slater et al.
(1992).
The spatial frequency of postsynaptic folds (‘openings/mm,’ Table II)
was determined by counting the number of fold openings in the region of the
muscle fiber surface immediately underlying the nerve terminal and divid-
ing this number by the length of the region of close nerve-muscle contact.
Neuromuscular Transmission
Neuromuscular transmission was assessed in detail in isolated EDL nerve-
muscle preparations from mice aged 6–8 wk. Preparations were main-
tained in gassed (95% O2–5% CO2) Liley’s solution at 20–228C. Muscle fi-
ber action potentials were blocked by exposure to 1026 M m-conotoxin,
GIIIB (Peptide Institute, Inc., Osaka, Japan). Two intracellular micro-
electrodes were placed in each muscle fiber in the vicinity of the NMJs.
The membrane potential was maintained at 275 mV by passing current
through one electrode while recording voltage with the other. Endplate
potentials were evoked by nerve stimulation (1 Hz) and recordings were
only made if the risetime (10–90%) of the endplate potentials was , 1 ms,
indicating proximity to the NMJ. At most NMJs studied, about 50 spontane-
ous miniature endplate potentials and 50 nerve-evoked (supramaximal stim-
ulation at 1 Hz) endplate potentials were recorded and then a similar num-
ber of miniature endplate currents and evoked endplate currents were
recorded using a two-electrode voltage clamp arrangement (holding po-
tential 275 mV). The features of these recordings in Table III were deter-
mined using software provided by John Dempster (Strathclyde, UK).
Quantal content was determined from the ratio of the mean values of the
endplate currents and miniature endplate currents at each NMJ. Studies
of miniature endplate potentials were also made in isolated diaphragm
preparations from mice ranging from 21–56-d-old.
Statistics
All tests for differences of mean values were made with two-tailed Stu-
dent’s t test.
Results
Generation of Utrophin-Deficient Mice
A clone containing utrophin exon 7 (by analogy to dystro-
Figure 2. Western analysis. Western analysis of wild-type and utrn2/2 skeletal muscle, lung, brain, diaphragm, kidney, and heart show-
ing normal levels of a-sarcoglycan (a) and b-dystroglycan (b), while reduced in mdx muscles. Dystrophin levels in utrn2/2 tissues ap-
pear similar to those of wild-type tissues (c). The 71-kD protein is one of the shorter alternative dystrophin transcripts (Dp71) which is
present at high levels in nonmuscle tissues.The Journal of Cell Biology, Volume 136, 1997 888
phin) flanked by 7 kb of intronic sequence was obtained
from a mouse 129/Sv library. A 59-end fragment was re-
moved for use as an external genomic probe in Southern
analysis and a neomycin cassette was introduced into the
exon to disrupt the reading frame (Fig. 1 a). Targeted R1
ES cell lines were obtained at a frequency of z10% (Fig.
1 b). Chimeras were generated to produce mice heterozy-
gous for the mutation (Fig. 1 c). Breeding resulted in Men-
delian ratios of wild type, heterozygotes, and homozygote
mice (Fig. 1 d). RT PCR analysis suggested aberrant splic-
ing of the targeted exon, with RNase protection assays
demonstrating significantly decreased utrophin mRNA
levels in the knockout mice (data not shown). Western
analysis of kidney, lung, and brain, the tissues in which
utrophin is normally most abundant, confirmed that utro-
phin is absent in the homozygotes (Fig. 1 e), a result con-
firmed by immunocytochemical analysis (see below). The
utrophin knockout mice are referred to as utrn2/2 mice.
Since the mutation is in the actin-binding domain, these
mice do not have altered expression of any shorter COOH-
terminal transcripts, such as G-utrophin (Blake et al., 1995).
Phenotype of the utrn2/2 Mice
In spite of the apparently complete absence of utrophin,
no phenotypic abnormalities were seen in utrn2/2 mice.
The newborn mice were of normal size and appearance,
suggesting that embryonic development had proceeded
normally. They ate and gained weight normally after birth
and have remained indistinguishable from wild type and
heterozygote litter mates to date (8 mo). There were no
signs of abnormal breathing or locomotor behavior and no
indication of muscle weakness in the utrn2/2 mice. The
mutant mice bred and reproduced at least as well as the in-
bred C57BL6/J strain from which they were partially de-
rived, suggesting that lack of utrophin does not affect
smooth muscle function involved in reproduction.
Histological examination of various tissues revealed no
obvious morphological abnormalities, even in kidney and
lung where utrophin is normally very highly expressed. To
check whether lack of utrophin caused defects in the glom-
erular filtration barrier, the level of protein in urine was
determined. Utrophin deficient mice did not show in-
creased protein levels in urine, suggesting that kidney
function is normal. Creatine kinase levels in the serum of
mice over three weeks old were normal, suggesting that
there is no degeneration of cardiac or skeletal muscle.
Western Analysis of utrn2/2 Mice
As described above, utrophin was undetectable by West-
ern blotting in the tissues studied (Fig. 1 e). To analyze the
effect of loss of utrophin on other members of the DPC,
levels of a-sarcoglycan and b-dystroglycan were studied in
various tissues. In muscle, a-sarcoglycan and b-dystrogly-
can were present at similar levels in wild-type and utrn2/2
mice (Fig. 2, a and b), while reduced in mdx muscles. b-Dys-
troglycan was also present at similar levels in utrn2/2 and
wild-type lung, kidney, brain, and heart (Fig. 2 b).
To see whether upregulation of dystrophin could ac-
count for the lack of phenotype observed in utrn2/2 mice,
dystrophin levels were compared to those in wild-type
Figure 3. Utrophin is absent
at the NMJ in utrn2/2 mice.
NMJs on permeabilized
whole SOL muscle fibers. (A
and  B) wild type; (C–F)
utrn2/2; (A, C, and E)
AChRs labeled with FITC-a-
BgTx; (B and D) utrophin la-
beled with antibody DRP3/
20C5; (F) no primary anti-
body. At NMJs from utrn2/2
mice, although AChR labeling
is present, no utrophin label-
ing can be seen. Bar, 20 mm.Deconinck et al. Postsynaptic Abnormalities in Utrophin-deficient Mice 889
mice. No increase in dystrophin abundance in utrn2/2
mice was seen in skeletal muscle, heart, or brain (Fig. 2 c).
However, the low abundance of utrophin in these tissues
implies that a low increase in dystrophin levels could be
sufficient and thus be undetected by Western analysis.
Structure of the Neuromuscular Junction
Immunocytochemical labeling studies were made to con-
firm the absence of utrophin at the NMJ of utrn2/2 mice.
In these studies, FITC-a-BgTx was used to identify the
NMJs on teased single soleus muscle fibers, labeled after
permeabilization with an antibody against the NH2-termi-
nal of utrophin (Fig. 3). In wild-type muscles, utrophin was
clearly labeled in a pattern essentially identical to that of
the AChRs (Fig. 3, A and B). No labeling for utrophin
could be detected at NMJs in utrn2/2 mice (Fig. 3, C–F).
The general structure of the NMJ was found to be essen-
tially normal in utrn2/2 mice (Fig. 4). Each muscle fiber
was innervated by a single motor axon which branched
within the junctional zone (Fig. 4, A and B). Extrasynaptic
nerve sprouts, present in a number of recently described
knockout mice lacking key synaptic proteins (e.g., rapsyn,
Gautam et al., 1995; agrin, Gautam et al., 1996 and MuSK,
DeChiara et al., 1996) were absent. Both AChE (Fig. 4, C
and D) and AChRs (Fig. 4, E and F) were highly concen-
trated at the NMJ and their distribution was indistinguish-
able from that in wild-type mice, indicating that these im-
Figure 4. Structure of the NMJ in
utrn2/2 and wild-type soleus mus-
cles. (A, C, E and G) utrn2/2 mice;
(B, D, F, and H) wild type. (A and B)
Motor axon terminals, impregnated
with silver, show no preterminal or
ultraterminal sprouting. (C and D)
AChE, demonstrated by a his-
tochemical method, is well localized
to the region of nerve contact. (E and
F) AChRs, labeled with TRITC-a-
BgTx, are highly concentrated in the
postsynaptic region. (g and h ),
AChRs, labeled with HRP-avidin-
biotin-a-BgTx, are concentrated in
the postsynaptic membrane at the
crests of the folds. Note that the num-
ber of fold openings is much less at
the utrn2/2 NMJ than in the wild type.
Bars: (A–F) 20 mm; (G and H) 1 mm.The Journal of Cell Biology, Volume 136, 1997 890
portant molecular components of the postsynaptic surface
are concentrated at the NMJ in the absence of utrophin.
The size of the NMJs, as indicated by the area of the re-
gion strongly labeled by TRITC-a-BgTx, was not signifi-
cantly different in utrn2/2 and control muscles (Table I).
To determine whether the ultrastructure of NMJs lack-
ing utrophin was normal, electron microscopic studies
were made of four different muscles (DIA, SOL, EDL,
and ETA). In all cases, the main ultrastructural features of
normal NMJs were present, including the nerve terminal
with its synaptic vesicles and mitochondria and the folded
postsynaptic surface (Fig. 4, G and H). At many NMJs in
utrn2/2 mice, the postsynaptic folding appeared less ex-
tensive than that in wild-type mice, an impression that was
confirmed by quantitative analysis (see below). Although
utrophin is normally expressed in Schwann cells, these did
not show any abnormal morphological features.
AChR Density and Folding at the
Neuromuscular Junction
The abundance of AChRs at the NMJ was examined using
labeled conjugates of a-BgTx (Table I). Studies with
125I-a-BgTx revealed a consistent reduction in the number
of a-BgTx binding sites per NMJ in utrn2/2 mice relative
to wild type in DIA, SOL, EDL, and ETA. The mean
binding per NMJ, averaged from all four muscles, was
57% of that in the wild type. This reduction in the number
of AChRs per NMJ could result from a reduction in the
overall size of the NMJs or in the density of AChRs within
the junctional region. Since there was no indication of re-
duced NMJ area, we tested the possibility of a reduction in
AChR density by quantifying the intensity of fluorescent
labeling by TRITC-a-BgTx of NMJs viewed en face in
whole muscle fibers. This was very significantly reduced,
relative to the wild type, in all three utrn2/2 muscles stud-
ied (DIA, SOL, and ETA; Table I).
This reduction in the intensity of TRITC-a-BgTx label-
ing, seen in the light microscope, might reflect a true de-
crease in AChR density, i.e., in the number of AChRs/unit
area of postsynaptic membrane. Alternatively, it might re-
flect a reduction in the amount of AChR-rich membrane
within the junctional region, which could result from de-
creased postsynaptic folding. At wild-type NMJs, the post-
synaptic membrane has infoldings occurring approximately
every 0.5 mm, extending inwards for z0.5–0.6 mm. AChRs,
seen labeled with biotinylated a-BgTx followed by an
electron-dense marker (Fig. 4 G), are highly concentrated
in the crests and upper third of the folds, but virtually ab-
sent from the troughs. In the utrn2/2 mice (Fig. 4 H),
AChRs were also well-localized at the tops of the folds but
the extent of folding appeared to be reduced. Analysis of
the frequency of folds at NMJs showed that in DIA and
SOL, the number of fold openings per mm of nerve-muscle
contact is significantly less in utrn2/2 mice than in wild type,
although this was not true in EDL and ETA (Table II).
When the data from all four muscles are pooled the frequency
of fold openings at utrn2/2 NMJs was 63% of that in con-
trols. This was not significantly different from the fractional
reduction in 125I-a-BgTx bound per NMJ (57%, see above).
The previous observations suggest that the reduction in
AChR abundance may be related to the decrease in fold-
ing. To test this idea further, studies of 125I-a-BgTx bind-
ing were undertaken at several times during early postna-
tal development, before and after the folds form (Fig. 5).
At birth and seven days postnatal, when little folding has
developed (Matthews-Bellinger and Salepeter, 1983; Be-
wick et al., 1996), 125I-a-BgTx binding was the same in the
utrophin deficient mice as in wild type. By 21 d postnatal,
when the extent of folding has nearly reached adult values,
a clear difference is evident.
Neuromuscular Transmission
To assess the effect of the absence of utrophin on synaptic
function, neuromuscular transmission was analyzed from
intracellular recordings of spontaneous and evoked synap-
tic potentials and currents studied in muscle fibers in
which the action potentials had been blocked with m-cono-
toxin. There was no difference in the amplitude or fre-
quency of spontaneous miniature endplate potentials in ei-
ther adult (8-wk-old) EDL (Table III) or in DIA from
mice 21, 38, or 56-d-old (data not shown). The amplitude
of evoked endplate potentials and endplate currents and
the quantal content (the number of acetylcholine quanta
released from the nerve by a single nerve impulse) were all
normal in the utrn2/2 mice, suggesting that ACh release
and action were normal. The decay time of the endplate
currents was also normal, suggesting that the kinetics of
the ACh-gated ion channels was not altered by the lack of
utrophin. While many features of neuromuscular transmis-
sion were normal in utrn2/2 mice, the amplitude of min-
Table I. a-Bungarotoxin Binding at NMJs in utrn2/2 and 
Wild-Type Mice
Muscle
utrn2/2
(3 107 sites/
NMJ)
Wild-type
(3 107 sites/
NMJ)
Ratio§
utrn2/2 to
wild-type P
DIA 0.62, 0.80 1.01, 1.25 0.63
125I-a-BgTx* SOL 0.40, 0.56 0.84, 0.99 0.52
EDL 0.66 1.20 0.55
ETA 0.52, 1.11 1.11, 1.76 0.57
TRITC-a-BgTx DIA 356 6 13 364 6 13 0.98 NS
Area (mm2)‡ SOL 494 6 29 508 6 16 0.97 NS
ETA 423 6 22 548 6 33 0.77 NS
Intensity‡ DIA 786 6 33 1234 6 57 0.64 ,0.0001
(Arbitrary units) SOL 701 6 22 971 6 31 0.72 ,0.0001
ETA 423 6 35 562 6 33 0.75 ,0.0001
*Each value is the number of 125I-a-BgTx binding sites/NMJ determined for one
muscle.
‡Values are mean 6 SD of a total of 20–60 NMJs in 1–3 muscles.
§Values are ratios of the mean value for utrn2/2 NMJs to that for wild-type NMJs.
Table II. Postsynaptic Folding at the NMJs in utrn2/2 and 
Wild-Type Mice
Muscle
utrn2/2*
(openings/mm)
Wild type*
(openings/mm) P
DIA 1.15 6 0.77 (22) 1.78 6 0.75 (23) ,0.01
SOL 0.65 6 0.49 (19) 2.07 6 0.59 (21) ,0.0001
EDL 1.96 6 1.06 (31) 2.16 6 0.78 (13) NS
ETA 1.21 6 0.68 (15) 1.92 6 1.17 (9) NS
*Values are mean 6 SD of (N) NMJs.Deconinck et al. Postsynaptic Abnormalities in Utrophin-deficient Mice 891
iature endplate currents was reduced by 20% in EDL. This
is consistent with a reduction in the density of AChRs.
Immunocytochemistry of Skeletal Muscle and NMJs
Immunofluorescence studies were made to investigate the
possible effects of the absence of utrophin on the abun-
dance of proteins normally closely associated with it in
muscle and at the NMJ. Labeling of unfixed cryostat sec-
tions of wild-type DIA with antibodies to utrophin con-
firmed that strong utrophin immunoreactivity was present
at all NMJs and absent in the extrajunctional region (Fig.
6 A). In contrast, no signal was seen at the NMJs from
utrn2/2 mice (Fig. 6 F) other than that seen in controls
with no primary antibody (Fig. 6, E and J). The results il-
lustrated were obtained with DRP1/12B6, an antibody to
the COOH terminus, but similar results were obtained
with DRP3/20C5, which is specific for the NH2 terminus
(see also Fig. 3). This rules out the possibility that short
forms of utrophin, which include one end or the other of
the whole protein, are expressed at the NMJ in utrn2/2
mice. Labeling with antibodies to dystrophin (Fig. 6, B and
G), b-dystroglycan (Fig. 6, C and H), and a-sarcoglycan
(data not shown), showed normal localization of these pro-
teins in the extrajunctional region of the muscle fiber and
at the NMJ in utrn2/2 mice. Labeling with an antibody
for rapsyn was absent in the extrajunctional region and
present at the NMJ in both control and utrn2/2 muscle
(Fig. 6, D and I).
Discussion
We have created mice carrying a targeted mutation at the
NH2-terminal of the utrophin gene. In studies of protein
expression by Western blotting and immunocytochemis-
try, using antibodies to both the NH2- and COOH-termi-
nals, utrophin levels were undetectable in these mice, even
at sites of normally high abundance such as blood vessels
and the NMJ. Surprisingly, the absence of utrophin had no
obvious effect on the phenotype of the utrn2/2 mice.
Nonetheless, the utrn2/2 mice showed changes in AChR
numbers and postsynaptic currents, and a highly signifi-
cant reduction in postsynaptic folds. Similar observations
have been made in utrophin-deficient mice in which the
utrophin gene is targeted at the COOH-terminal end
(Grady et al., 1997). Utrophin, like dystrophin, is thought
to have many shorter isoforms, most containing either
COOH-terminal or NH2-terminal sequences (Blake et al.,
1995; Nguyen thi Man et al., 1995). The similarity in the ef-
fects of targeting the COOH-terminal and NH2-terminal
regions suggests that these shorter isoforms are not essen-
tial for a normal phenotype.
In spite of its suggestive distribution within the NMJ, the
absence of utrophin had remarkably little effect on the
overall structure and function of the NMJ. This is in strik-
ing contrast to the devastating effects of knocking out sev-
eral other postsynaptic molecules (rapsyn, Gautam et al.,
1995; agrin, Gautam et al., 1996; MuSK, DeChiara et al.,
1996). In particular, the localization of AChRs within the
junctional region, as seen with both the light- and electron
microscopes, appeared normal. Thus, in spite of its very
close spatial association with the AChRs throughout de-
velopment and in the adult, utrophin does not appear to
be essential for AChR localization or for the development
of functional NMJs, as has been suggested (Phillips et al.,
1993; Campanelli et al., 1994). In view of the close associa-
tion between RAPsyn and AChRs, one might expect simi-
larly reduced levels of RAPsyn, but preliminary immuno-
fluorescence studies show strong labeling.
While many features of the NMJs in utrn2/2 mice were
normal, two abnormalities were observed; a reduction in
the number of AChRs per NMJ and a reduction in the fre-
quency of postsynaptic infoldings. These two findings may
be related. Since AChRs are particularly concentrated in
the region of the folds nearest their opening onto the ex-
tracellular space, the observed reduction in the number of
those openings would be expected to reduce the area of
membrane available to accommodate AChRs. This view is
supported by our finding that the decreased abundance of
AChRs in utrn2/2 mice is not detectable until the post-
synaptic folds form during development. The process by
which folds form, and the factors which may influence that
process, are not understood. The decrease in the spatial
frequency of folds was more obvious in diaphragm and so-
leus than in EDL and ETA. The former muscles are nor-
mally active either continuously (soleus) or in small bursts
Figure 5. 125I-a-BgTx binding in hemidiaphragms during postna-
tal development. Measurements of NMJ-specific binding per hemi-
diaphragm were made from individual litters of wild-type and
utrn2/2 mice at different time points and are given as mean 6
SD (N 5 1–4). A clear difference in a-BgTx binding between
utrn2/2 and wild-type muscles is only seen once the postsynaptic
folds have formed at 21 d (P , 0.01, n 5 6). At 38 d, only one hemi-
diaphragm was examined from each mouse, but in another litter
of mice, the results were also significantly different at 49 and 56 d
(P , 0.01 and P , 0.05, respectively).
Table III. Neuromuscular Transmission in the EDL Muscle of 
utrn2/2 and Wild-Type Mice
utrn2/2* Wild-type* P
mEPP amplitude (mV) 0.46 6 0.18 (43) 0.51 6 0.28 (50) NS
mEPP frequency (Hz) 3.42 6 2.26 (39) 3.48 6 2.45 (47) NS
EPP amplitude (mV) 22.6 6 6.9 (34) 25.4 6 7.2 (24) NS
mEPC amplitude (mA) 2.48 6 0.81 (35) 3.10 6 1.02 (35) ,0.01
EPC amplitude (mA) 197.1 6 125.8 (28) 253.3 6 117.2 (18) NS
EPC decay time 
constant (ms) 1.19 6 0.30 (26) 1.17 6 0.28 (18) NS
Quantal content 81.0 6 42.1 (26) 94.9 6 34.6 (16) NS
*Values are mean 6 SD of data from a total of (N) NMJs, from two muscles, isolated
from 8-wk-old mice. mEPP, miniature endplate potential; EPP, endplate potential;
mEPC, miniature endplate current; EPC, endplate current.The Journal of Cell Biology, Volume 136, 1997 892
related to the respiratory cycle (diaphragm) while the lat-
ter are fast twitch muscles which fire relatively infre-
quently and in short, high-frequency bursts (Hennig and
Lømo, 1985). This suggests that the pattern of activity may
have some influence on the formation or maintenance of
folds. Postsynaptic folding is also reduced in mdx mice
which lack dystrophin (Bulfield et al., 1984; Sicinski et al.,
1989; Torres and Duchen, 1987; Lyons and Slater, 1991).
While this may reflect a rather nonspecific effect of abnor-
malities of the postsynaptic cytoskeleton on the incidence
of folds, it may also be that cycles of muscle fiber degener-
ation and regeneration, which are present in mdx but not
utrn2/2 mice, result in reduced folding.
The normal appearance and behavior of utrn2/2 mice
suggest that the role of utrophin, in spite of its widespread
distribution, is nonessential in mouse. Alternatively, the
role of utrophin may be important during old age or in re-
sponse to tissue damage, for example during regeneration
of muscle. Another possibility is that proteins which can
compensate for the function of utrophin are upregulated.
The most obvious candidate for such a compensating pro-
tein is dystrophin. However, we have so far found no evi-
dence for increased abundance of dystrophin or a de novo
appearance at sites such as blood vessels which are nor-
mally rich in utrophin. Relocalization of dystrophin to the
crests of the folds can unfortunately not be investigated.
Frozen sections do not allow resolution between the crest
and the bottom of the junctional folds, and there are no
Figure 6. Postsynaptic proteins at the NMJ of wild-type and utrn2/2 mice. Immunolabeling of transverse frozen sections, including
junctional and extrajunctional regions of the surface of DIA fibers, is shown for wild-type (A–E) and utrn2/2 (F–J) fibers. For each
pair of images, the left panel shows the NMJ, labeled with FITC-a-BgTx. The right panel shows immunolabeling visualized with
TRITC-conjugated second antibody. The antibodies used were (A and F) utrophin (DRP1/12B6); (B and G) dystrophin (DY8/6C5); (C
and H) b-dystroglycan (43DAG/8D5); (D and I) rapsyn (rabbit polyclonal against recombinant rapsyn); (E and J) no primary antibody.
While utrophin labeling is absent at utrn2/2 NMJs, the pattern of labeling of all other antibodies is the same in utrn2/2 and wild-type
NMJs. For each antibody, the images of wild-type and utrn2/2 NMJs have been printed under equivalent conditions. Bar, 20 mm.Deconinck et al. Postsynaptic Abnormalities in Utrophin-deficient Mice 893
antibodies available that allow dystrophin to be visualized
adequately by EM immunolabeling.
In muscular dystrophies resulting from decreased dys-
trophin abundance, both in man and in mdx mice, there is
a parallel reduction in the abundance of many of the pro-
teins of the DPC (Ervasti et al., 1990; Ohlendieck and
Campbell, 1991; Sewry et al., 1994). In utrn2/2 mice the
two members of the DPC studied, b-dystroglycan was
clearly present in lung and kidney where utrophin is nor-
mally most abundant but dystrophin is not expressed. In
the absence of an upregulation of dystrophin, this suggests
that utrophin is not essential for the maintenance or local-
ization of the proteins of the DPC. Nonetheless, the possi-
bility remains that this role can be played by isoforms of
dystrophin or utrophin, not recognized by the antibodies
we used, that may be present normally in these tissues or
upregulated in the face of decreased utrophin abundance.
Both reduced AChR abundance and decreased postsyn-
aptic folding are features of a number of congenital myas-
thenic syndromes (CMS) in man, conditions in which im-
pairment of neuromuscular transmission leads to muscle
weakness and abnormal fatiguability (reviewed in Engel
et al., 1993; Shillito et al., 1993; Vincent et al., 1996). The
molecular and genetic basis of this heterogeneous group of
disorders is poorly understood in most cases (see Engel,
1993; Engel et al., 1996; Sine et al., 1995; Ohno et al., 1995,
1996). However, in some patients with reduced AChRs
and reduced folds, there is a profound reduction in the
abundance of utrophin at the NMJ, although other pro-
teins (e.g., dystrophin and b-dystroglycan) remain concen-
trated in the postsynaptic region (Slater et al., 1994).
While this suggests some sort of link between AChRs and
utrophin, the nature of that link remains unclear.
In conclusion, the absence of utrophin in utrn2/2 mice
results in mild abnormalities at the NMJ but no other signs
of an abnormal phenotype. The similarity of the changes
at the NMJ to those in some forms of CMS suggest that
utrophin expression should be investigated in such pa-
tients, particularly since the autosomal utrophin gene rep-
resents such a large target for mutation.
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